5616-81-9

Basic information

• Product Name: tert-Butyl sarcosinate hydrochloride
• Synonyms: H-SAR-OTBU HCL;H-SAR-OBUT HCL;N-METHYLGLYCINE T-BUTYL ESTER HYDROCHLORIDE;N-ME-GLY-OTBU HCL;TERT-BUTYL SARCOSINATE HYDROCHLORIDE;TERT-BUTYL SARCOSINATE HCL;SARCOSINE TERT-BUTYL ESTER HYDROCHLORIDE;SARCOSINE T-BUTYL ESTER HYDROCHLORIDE SALT
• CAS NO: 5616-81-9
• Molecular Formula: C₇H₁₅NO₂
• Molecular Weight: 181.66
• EINECS: 1533716-785-6
• Product Categories: Sarcosine [Sar];Unusual Amino Acids;Amino hydrochloride
• Mol File: 5616-81-9.mol
• Article Data: 19

Chemical Properties

• Melting Point: 137-141 °C (dec.)
• Boiling Point: 168.5 °C at 760 mmHg
• Flash Point: 55.7 °C
• Appearance: White/Powder
• Density: 0.928 g/cm³
• Vapor Pressure: 1.62mmHg at 25°C
• Refractive Index: 1.422
• Storage Temp.: -15°C
• Solubility: Soluble in methanol (0.3 gram in 2 mL MeOH).
• PKA: 7.63±0.10(Predicted)
• CAS DataBase Reference: tert-Butyl sarcosinate hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: tert-Butyl sarcosinate hydrochloride(5616-81-9)
• EPA Substance Registry System: tert-Butyl sarcosinate hydrochloride(5616-81-9)

Safety Data

• WGK Germany: 3
• Hazardous Substances Data: 5616-81-9(Hazardous Substances Data)

Usage

Chemical Properties

White crystalline powder

Uses

Different sources of media describe the Uses of 5616-81-9 differently. You can refer to the following data:
1. Sarcosine tert-butyl ester hydrochloride, is used as an important raw material and intermediate used in organic Synthesis, pharmaceuticals, agrochemicals and dyestuff.
2. Sarcosine tert-butyl ester hydrochloride may be used for the synthesis of (N-(((tert-butyl)oxycarbonyl)methyl)-N-methylcarbamoyl)methyl(2S)-2-(6-methoxy(2-naphthyl))propanoate.

InChI:InChI=1/C7H15NO2/c1-7(2,3)10-6(9)5-8-4/h8H,5H2,1-4H3

Upstream product

• 101644-79-5 α-tert-butyl N-(benzyloxycarbonyl)-N-methylglycinate 
• 107-59-5 tert-Butyl chloroacetate 
• 74-89-5 methylamine 
• 107-97-1 sarcosine 
• 115-11-7 isobutene 
• 5292-43-3 bromoacetic acid tert-butyl ester 
• 540-88-5 acetic acid tert-butyl ester 

Downstream Products

• 117194-57-7 Z-Abu-Sar-O-(t-Bu) 
• 84569-77-7 valyl>sarkosin-tert-butylester-chlorid 
• 87544-37-4 (3-Benzoyl-1-methyl-thioureido)-acetic acid tert-butyl ester 
• 5616-82-0 N-(benzyloxycarbonyl)prolylsarcosine tert-butyl ester 
• 158804-98-9 (S)-2-Benzyloxycarbonylamino-4-(tert-butoxycarbonylmethyl-methyl-carbamoyl)-butyric acid tert-butyl ester 
• 887923-75-3 2-[(tert-butoxycarbonylmethyl-methyl-amino)-methyl]-4-(tert-butyl-diphenyl-silanyloxy)-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 144036-71-5 tert-butyl 2-(1-methylhydrazinyl)acetate 
• 158804-99-0 (S)-4-(tert-Butoxycarbonylmethyl-methyl-carbamoyl)-2-{4-[(2-methyl-4-oxo-3,4-dihydro-quinazolin-6-ylmethyl)-prop-2-ynyl-amino]-benzoylamino}-butyric acid tert-butyl ester 
• 158629-40-4 N-(benzyloxycarbonyl)-D-phenylalaninylprolylsarcosine tert-butyl ester 
• 158629-42-6 N-(benzyloxycarbonyl)-D-(O-methyl)tyrosylprolylsarcosine tert-butyl ester 
• 158629-45-9 N-(tert-butoxycarbonyl)-D-(O-benzyl)tyrosylprolylsarcosine tert-butyl ester 
• 158629-41-5 N-(benzyloxycarbonyl)threonyl-D-phenylalaninylprolylsarcosine tert-butyl ester 
• 158629-43-7 N-(benzyloxycarbonyl)threonyl-D-(O-methyl)tyrosylprolylsarcosine tert-butyl ester 
• 158629-47-1 N-(benzyloxycarbonyl)threonyl-D-(O-benzyl)tyrosylprolylsarcosine tert-butyl ester 

Relevant articles and documents

Discovery of potent small molecule PROTACs targeting mutant EGFR

Epidermal growth factor receptor (EGFR) is an important therapeutic target for the treatment of non-small cell lung cancer. A number of efficacious EGFR tyrosine kinase inhibitors have been developed. However, acquired drug resistance largely encumbered their clinical practicability. Therefore, there is an urgent need to develop new therapeutic regime. Herein, we designed and synthesized a set of EGFR-targeting small molecule PROTACs which showed promising efficacy. In particular, VHL-recruiting compound P3 showed potent anti-proliferative activity against HCC827 and H1975 cell lines with IC50 values of 0.83 and 203.01 nM, respectively. Furthermore, both EGFRdel19 and EGFRL858R/T790M could be significantly induced to be degraded under treatment of P3 with DC50 values of 0.51 and 126.2 nM, respectively. Compound P3 was able to dramatically suppress EGFR pathway signal transduction. Moreover, compound P3 could significantly induce cell apoptosis, arrest cell cycle and suppress cell colony formation. In addition, we identified that ubiquitination was indispensable in the degradation process, and found that the degradation was related to autophagy. Our work would provide an alternative approach for development of potentially effective EGFR degraders and give a new clue for investigation of PROTAC-induced protein degradation.

Challenges in the Development of a Thiol-Based Broad-Spectrum Inhibitor for Metallo-β-Lactamases

Pathogens, expressing metallo-β-lactamases (MBLs), become resistant against most β-lactam antibiotics. Besides the dragging search for new antibiotics, development of MBL inhibitors would be an alternative weapon against resistant bacterial pathogens. Inhibition of resistance enzymes could restore the antibacterial activity of β-lactams. Various approaches to MBL inhibitors are described; among others, the promising motif of a zinc coordinating thiol moiety is very popular. Nevertheless, since the first report of a thiol-based MBL inhibitor (thiomandelic acid) in 2001, no steps in development of thiol based MBL inhibitors were reported that go beyond clinical isolate testing. In this study, we report on the synthesis and biochemical characterization of thiol-based MBL inhibitors and highlight the challenges behind the development of thiol-based compounds, which exhibit good in vitro activity toward a broad spectrum of MBLs, selectivity against human off-targets, and reasonable activity against clinical isolates.

Method of use of pharmaceutical formulations for the treatment of apicomplexan diseases in animals

The present invention is directed to the method of use of effective pharmaceutical formulations for the treatment of diseases caused by apicomplexan parasites, said formulation comprised of a salicylanilide or salicylanilide derivative, disclosed herein,